title: In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection.
abstract: A novel oxazolidinone, AM 7359, was evaluated in two mouse models of Staphylococcus aureus infection. AM 7359 and linezolid were equally efficacious in a methicillin-susceptible S. aureus organ burden model and a methicillin-resistant S. aureus localized infection model. However, AM 7359 was eightfold more efficacious than linezolid against a linezolid- and methicillin-resistant S. aureus strain in this localized (thigh) infection model.
authors.affiliation: Department of Infectious Diseases, Merck Research Laboratories, Rahway, NJ 07065, USA. charles_gill@merck.com
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Gill
authors.forename: George K
authors.initials: GK
authors.lastname: Abruzzo
authors.forename: Amy M
authors.initials: AM
authors.lastname: Flattery
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Misura
authors.forename: Ken
authors.initials: K
authors.lastname: Bartizal
authors.forename: Emily J
authors.initials: EJ
authors.lastname: Hickey
mesh_terms: D000081:Acetamides / Q000627:therapeutic use; D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004305:Dose-Response Relationship, Drug; D007275:Injections, Intravenous; D000069349:Linezolid; D016106:Methicillin Resistance; D051379:Mice; D008809:Mice, Inbred C3H; D023303:Oxazolidinones / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: C523767:AM-7359; D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid